Ribavirin Injection

1 Pharmacology Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of many viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. 2 Toxicological animal experiments have found that this product can induce benign tumors of the breast, pancreas, pituitary and adrenal glands, but its carcinogenicity to humans has not been confirmed. The drug can cause malformations of the head, palate, eyes, jaw, bones and gastrointestinal tract in animals such as hamsters, and reduce the survival of offspring, but primate experiments have not found any effect of the drug on the fetus. Cardiac damage occurred in mice, rats, and monkeys given oral ribavirin at doses of 30, 36, and 120 mg/kg or more for 4 weeks (equivalent to human doses of 4.8, 12.3, and 111.4 mg/kg for a 5 kg child or 2.5, 5.1, and 40 mg/kg for a 60 kg adult).

The main ingredient of this product is ribavirin, whose chemical name is 1-beta;-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide.

This product is a colorless clear liquid.

It is mainly used for viral pneumonia and bronchitis caused by respiratory syncytial virus (RSV). It is used for the prevention and treatment of epidemic hemorrhagic fever and Lassa fever. The early application of this product in the fever stage can shorten the fever period, alleviate kidney and blood vessel damage and poisoning symptoms. Topical application can treat herpes simplex virus keratitis.

Dilute with sodium chloride injection or 5% glucose injection to a solution containing 1 mg per 1 ml and then slowly drip intravenously. Adults take 0.5 g at a time, twice a day, and children take 10-15 mg/kg per day according to body weight, divided into 2 doses. Each drip should last for more than 20 minutes, and the course of treatment is 3-7 days.

Common adverse reactions include anemia and fatigue, which disappear after stopping the drug. Less common adverse reactions include fatigue, headache, insomnia, loss of appetite, nausea, vomiting, etc., and can cause a decrease in red blood cells, white blood cells and hemoglobin.

It is forbidden for people who are allergic to this product and pregnant women.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Contraindicated for pregnant women. Precautions for the elderly: Not recommended for the elderly.

This product has an antagonistic effect when used together with zidovudine, because this product can inhibit the conversion of zidovudine into active zidovudine phosphate.

Keep tightly closed.

1ml:0.1g

30 months

Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.

• Founded in:

  1999-11-12

• Address:

  No. 166, North side of Xinxing Road, west side of Zhenxing Road, Liangyuan District, Shangqiu City

• Tax NO.:

  91411400716735619N

• Registered Funds:

  83.29 million yuan

• Website:

  Log in to view

• Email:

  Log in to view